US6890546B2
(en)
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US7357942B2
(en)
*
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
US7960405B2
(en)
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
DE60310383T2
(de)
*
|
2002-01-29 |
2007-09-20 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
Vorbeugung von gewebeadhäsion
|
US20030176455A1
(en)
*
|
2002-03-13 |
2003-09-18 |
Wyeth |
Method of inhibiting cell death
|
BR0311173A
(pt)
|
2002-05-16 |
2005-03-15 |
Novartis Ag |
Uso de agentes de ligação do receptor de edg em câncer
|
JP4372001B2
(ja)
|
2002-05-27 |
2009-11-25 |
ノバルティス アクチエンゲゼルシャフト |
ビス芳香族アルカノール類
|
WO2004022124A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Abbott Laboratories |
Medical device having hydration inhibitor
|
RU2478378C2
(ru)
|
2002-09-24 |
2013-04-10 |
Новартис Аг |
Органические соединения
|
EP1628967B1
(en)
|
2003-05-19 |
2014-04-09 |
Irm Llc |
Immunosuppressant compounds and compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
EP1768662A2
(en)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Small molecule immunopotentiators and assays for their detection
|
WO2006050461A1
(en)
|
2004-10-28 |
2006-05-11 |
Wyeth |
Use of an mtor inhibitor in treatment of uterine leiomyoma
|
GB0504544D0
(en)
|
2005-03-04 |
2005-04-13 |
Novartis Ag |
Organic compounds
|
US20090062909A1
(en)
|
2005-07-15 |
2009-03-05 |
Micell Technologies, Inc. |
Stent with polymer coating containing amorphous rapamycin
|
WO2007011707A2
(en)
|
2005-07-15 |
2007-01-25 |
Micell Technologies, Inc. |
Polymer coatings containing drug powder of controlled morphology
|
CN101282745B
(zh)
|
2005-07-25 |
2015-04-29 |
新兴产品开发西雅图有限公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
AU2006284922B2
(en)
|
2005-08-30 |
2012-01-19 |
University Of Miami |
Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
|
WO2007056118A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
US7700614B2
(en)
*
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
WO2007127363A2
(en)
|
2006-04-26 |
2007-11-08 |
Micell Technologies, Inc. |
Coatings containing multiple drugs
|
US7812032B2
(en)
*
|
2006-07-25 |
2010-10-12 |
Abbott Laboratories |
Crystalline forms of rapamycin analogs
|
KR20090035716A
(ko)
*
|
2006-07-25 |
2009-04-10 |
아보트 러보러터리즈 |
라파마이신 유사체의 결정형 형태
|
US7820812B2
(en)
|
2006-07-25 |
2010-10-26 |
Abbott Laboratories |
Methods of manufacturing crystalline forms of rapamycin analogs
|
US11426494B2
(en)
|
2007-01-08 |
2022-08-30 |
MT Acquisition Holdings LLC |
Stents having biodegradable layers
|
WO2008086369A1
(en)
|
2007-01-08 |
2008-07-17 |
Micell Technologies, Inc. |
Stents having biodegradable layers
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
JP5647098B2
(ja)
|
2008-03-21 |
2014-12-24 |
ザ ユニヴァーシティー オヴ シカゴ |
オピオイド拮抗薬とmTOR阻害薬を用いた治療
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
EP3360586B1
(en)
|
2008-04-17 |
2024-03-06 |
Micell Technologies, Inc. |
Stents having bioabsorbable layers
|
EP2303250A1
(en)
|
2008-06-20 |
2011-04-06 |
Novartis AG |
Paediatric compositions for treating1 multiple sclerosis
|
WO2010009335A1
(en)
|
2008-07-17 |
2010-01-21 |
Micell Technologies, Inc. |
Drug delivery medical device
|
US9510856B2
(en)
|
2008-07-17 |
2016-12-06 |
Micell Technologies, Inc. |
Drug delivery medical device
|
BRPI0923176B8
(pt)
|
2008-12-18 |
2021-05-25 |
Novartis Ag |
forma cristalina do sal de hemifumarato de ácido 1-(4-{1-[(e)- 4-ciclo-hexil-3-trifluormetil-benzilóxi-imino]-etil}-2- etil-benzil)-azetidina-3-carboxílico e composição farmaceutica
|
MX2011006610A
(es)
|
2008-12-18 |
2011-06-30 |
Novartis Ag |
Nueva forma polimorfica de acido 1-(4-{l-[(e)-4-ciclohexil-3 -trifluorometil-benciloxi-imino]-etil)-2-etil-bencil)-azetidin-3 carboxilico.
|
AU2009335887A1
(en)
|
2008-12-18 |
2011-06-30 |
Novartis Ag |
New salts
|
CN102481195B
(zh)
|
2009-04-01 |
2015-03-25 |
米歇尔技术公司 |
涂覆支架
|
EP2419058B1
(en)
|
2009-04-17 |
2018-02-28 |
Micell Technologies, Inc. |
Stents having controlled elution
|
JP2013501057A
(ja)
|
2009-08-03 |
2013-01-10 |
ユニバーシティー・オブ・マイアミ |
制御性t細胞のinvivoにおける増殖
|
CN102770129A
(zh)
|
2009-10-30 |
2012-11-07 |
阿里亚德医药股份有限公司 |
治疗癌症的方法和组合物
|
WO2011097103A1
(en)
|
2010-02-02 |
2011-08-11 |
Micell Technologies, Inc. |
Stent and stent delivery system with improved deliverability
|
JP5844287B2
(ja)
|
2010-02-11 |
2016-01-13 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
第xia因子阻害剤としてのマクロ環
|
CA2797110C
(en)
|
2010-04-22 |
2020-07-21 |
Micell Technologies, Inc. |
Stents and other devices having extracellular matrix coating
|
KR101620661B1
(ko)
|
2010-04-27 |
2016-05-12 |
로슈 글리카트 아게 |
어푸코실화된 CD20 항체와 mTOR 억제제의 복합 요법
|
CN102234288B
(zh)
*
|
2010-05-06 |
2014-07-02 |
上海医药工业研究院 |
唑他莫司的制备方法
|
WO2012009684A2
(en)
|
2010-07-16 |
2012-01-19 |
Micell Technologies, Inc. |
Drug delivery medical device
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
WO2013012689A1
(en)
|
2011-07-15 |
2013-01-24 |
Micell Technologies, Inc. |
Drug delivery medical device
|
CA2851810C
(en)
|
2011-10-14 |
2020-01-07 |
Bristol-Myers Squibb Company |
Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
US10188772B2
(en)
|
2011-10-18 |
2019-01-29 |
Micell Technologies, Inc. |
Drug delivery medical device
|
MX351848B
(es)
|
2012-10-12 |
2017-10-31 |
Bristol Myers Squibb Co |
Formas cristalinas de inhibidor del factor xia.
|
US9403774B2
(en)
|
2012-10-12 |
2016-08-02 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
EP2906552B1
(en)
|
2012-10-12 |
2017-11-22 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
EP2809675A4
(en)
*
|
2012-11-30 |
2015-08-12 |
Hangzhou Zylox Pharma Co Ltd |
ANALOGUE OF RAPAMYCIN AND METHODS OF MANUFACTURING THE SAME
|
KR20210041631A
(ko)
|
2013-01-09 |
2021-04-15 |
유니버시티 오브 마이애미 |
TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
|
EP2967803B1
(en)
|
2013-03-12 |
2023-12-27 |
Micell Technologies, Inc. |
Bioabsorbable biomedical implants
|
JP6479763B2
(ja)
|
2013-03-25 |
2019-03-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
第xia因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
|
CN105377318A
(zh)
|
2013-05-15 |
2016-03-02 |
脉胜医疗技术公司 |
可生物吸收的生物医学植入物
|
WO2015073644A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Ag |
Mtor inhibitors for enhancing the immune response
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
CN103739616B
(zh)
*
|
2013-12-27 |
2015-12-30 |
福建省微生物研究所 |
含噻唑基雷帕霉素类衍生物及其应用
|
WO2015108912A1
(en)
|
2014-01-16 |
2015-07-23 |
MUSC Foundation for Research and Development |
Targeted nanocarriers for the administration of immunosuppressive agents
|
WO2015116886A1
(en)
|
2014-01-31 |
2015-08-06 |
Bristol-Myers Squibb Company |
Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
|
NO2760821T3
(zh)
|
2014-01-31 |
2018-03-10 |
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
EP3122376A4
(en)
|
2014-03-27 |
2017-12-20 |
The Brigham and Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
PL3129470T3
(pl)
|
2014-04-07 |
2021-11-29 |
Novartis Ag |
Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
|
JP2017518307A
(ja)
|
2014-06-02 |
2017-07-06 |
チルドレンズ メディカル センター コーポレーション |
免疫調節のための方法および組成物
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
WO2016036893A1
(en)
|
2014-09-04 |
2016-03-10 |
Bristol-Myers Squibb Company |
Diamide macrocycles that are fxia inhibitors
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
US10774388B2
(en)
|
2014-10-08 |
2020-09-15 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CN107847491A
(zh)
|
2015-05-20 |
2018-03-27 |
诺华公司 |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
WO2017081624A1
(en)
|
2015-11-11 |
2017-05-18 |
Novartis Ag |
Uses of myostatin antagonists, combinations containing them and uses thereof
|
CN109641947B
(zh)
|
2016-07-20 |
2023-04-14 |
犹他大学研究基金会 |
Cd229 car t细胞及其使用方法
|
RU2019113504A
(ru)
|
2016-10-07 |
2020-11-09 |
Новартис Аг |
Химерные антигенные рецепторы для лечения рака
|
WO2018096402A1
(en)
|
2016-11-23 |
2018-05-31 |
Novartis Ag |
Methods of enhancing immune response with everolimus, dactolisib or both
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
CA3107352A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
CA3107349A1
(en)
|
2018-07-23 |
2020-01-30 |
Enclear Therapies, Inc. |
Methods of treating neurological disorders
|
JP2022526671A
(ja)
|
2019-04-11 |
2022-05-25 |
エンクリアー セラピーズ, インク. |
脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
|
WO2022098642A1
(en)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
JP2024529341A
(ja)
|
2021-07-15 |
2024-08-06 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
粒子が付着している細胞に関連する組成物および方法
|
CN116082362B
(zh)
*
|
2023-01-04 |
2024-05-10 |
山东大学 |
一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用
|